Acadian Asset Management
ATNM icon

Acadian Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Acadian Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$596K Sell
600,819
-5,520
-0.9% -$6.57K ﹤0.01% 1313
2025
Q4 		$823K Buy
606,339
+116,762
+24% +$170K ﹤0.01% 1168
2025
Q3 		$782K Sell
489,577
-2,366
-0.5% -$3.85K ﹤0.01% 1111
2025
Q2 		$687K Sell
491,943
-12,095
-2% -$18.1K ﹤0.01% 1071
2025
Q1 		$810K Buy
504,038
+4,778
+1% +$6.07K ﹤0.01% 978
2024
Q4 		$628K Buy
499,260
+45,566
+10% +$70.7K ﹤0.01% 1025
2024
Q3 		$851K Buy
+453,694
New +$1.79M ﹤0.01% 957
2023
Q1 		– Sell
-25,693
Closed -$273K – 1737
2022
Q4 		$273K Buy
25,693
+9,930
+63% +$101K ﹤0.01% 1210
2022
Q3 		$115K Buy
+15,763
New +$98K ﹤0.01% 1332

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Acadian Asset Management's ATNM Position: Q1 2026 in Review

Acadian Asset Management reduced its Actinium Pharmaceuticals (ATNM) stake by 0.91% in Q1 2026, selling an estimated $6.57K and leaving 600,819 shares worth $596K. The position accounts for ﹤0.01% of the portfolio, ranked #1313.

Acadian Asset Management first reported a position in ATNM in Q3 2022 and has held it in 9 quarters since. The position peaked at $851K in Q3 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Acadian Asset Management held 600,819 shares of Actinium Pharmaceuticals worth $596K as of Q1 2026.
  • Acadian Asset Management sold 5,520 Actinium Pharmaceuticals shares in Q1 2026, an estimated $6.57K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1313 holding.
  • Acadian Asset Management first reported a position in Actinium Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
  • Acadian Asset Management's Actinium Pharmaceuticals position peaked at $851K in Q3 2024.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.